{
  "docId": "019de076-34c7-7046-ba4a-b568cf89a7c9",
  "docSlug": "e7da6c89bd00edfe5ee10f12333167ff",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 56,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "traction",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 22,
  "notes": "The chart displays adverse events occurring in >=10% of patients (n=15).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-34c7-7046-ba4a-b568cf89a7c9/22",
  "deckHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9",
  "deckJsonHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9.json",
  "deckAnchorHref": "/decks/019de076-34c7-7046-ba4a-b568cf89a7c9#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.4,
        "x": 0.246,
        "y": 0.148
      },
      "kind": "chart",
      "text": "Treatment-related Adverse Events, in >=10% patients",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e45165d-3c1e-4c80-8b3c-1a5345cbe91b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.06,
        "x": 0.46,
        "y": 0.78
      },
      "kind": "legend",
      "text": "Grade 1, Grade 2, Grade 3, Grade 4",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3ba2e72f-ac65-4b25-b5f4-721a37ef3c3d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "paragraph",
      "text": "AE, adverse event; BID, twice daily; QD, once daily. Phase 1 data in NRASm melanoma from De Braud et al AACR 2022",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "554e8b2e-604c-4492-aa9d-5785187005db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Naporafenib + trametinib demonstrated a favorable, manageable safety profile",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e52bb0f4-838a-4072-bf17-42f04b286eb7",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 42,
      "from": 16,
      "beatId": "de59f7d9-38c9-46a9-8877-a3655888462f",
      "arcName": "Rags to Riches",
      "arcSlug": "rags-to-riches",
      "beatName": "Erasca's pipeline and clinical data",
      "beatSlug": "rags-to-riches-rising-success",
      "evidence": "Slides 16-42 present Erasca's pipeline and clinical data",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Development",
      "parentBeatSlug": "development"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}